HTN Differential Diagnosis: Key Considerations for Accurate Diagnosis

Introduction

Hypertension (HTN), currently defined as systolic blood pressure (SBP) consistently at or above 130 mm Hg and/or diastolic blood pressure (DBP) at or above 80 mm Hg, stands as a pervasive chronic health concern globally. Characterized by persistently elevated arterial pressure, HTN is a major contributor to severe cardiovascular events, including stroke, myocardial infarction, heart failure, and renal failure. While the definition and classification of hypertension have evolved, the medical consensus emphasizes initiating treatment for readings consistently at or above 140/90 mm Hg, aiming for a therapeutic target of 130/80 mm Hg or lower for most patients. Accurate diagnosis is paramount, and a crucial aspect of managing hypertension effectively involves a thorough Htn Differential Diagnosis. This process is essential to distinguish essential hypertension from secondary forms and other conditions that may mimic or exacerbate high blood pressure. This article provides a detailed review of hypertension, emphasizing the importance of differential diagnosis, etiology, epidemiology, evaluation, and management strategies, drawing upon established guidelines and recent clinical findings.

Etiology of Hypertension

The majority of hypertension cases are classified as essential or idiopathic hypertension, meaning they arise without a clearly identifiable underlying cause. Genetic predisposition and environmental factors play significant roles. A well-documented environmental factor is dietary salt intake. Research suggests a link between increased salt consumption and a higher risk of developing hypertension.[1] Individual salt sensitivity, often genetically determined, further influences this relationship, with approximately 50% to 60% of hypertensive individuals being salt-sensitive.[2],[3],[4] This sensitivity means their blood pressure is more significantly affected by changes in sodium intake.

Epidemiology of Hypertension

Globally, hypertension affects over one billion adults, representing as much as 45% of the adult population.[5] Its prevalence is consistently high across diverse socioeconomic groups and increases significantly with age, affecting up to 60% of individuals over 60 years old.[5]

Data from the 2010 Global Health Survey, published in The Lancet, identified hypertension as the leading cause of death and disability-adjusted life years worldwide since 1990. In the United States, hypertension is a more significant risk factor for cardiovascular disease-related deaths than any other modifiable risk factor, second only to smoking as a preventable cause of death.[6]

Projections indicate a potential 15% to 20% increase in hypertension cases, potentially reaching 1.5 billion individuals by 2025.[7] This escalating prevalence underscores the urgent need for effective diagnostic and management strategies, including a robust approach to HTN differential diagnosis.

Pathophysiology of Hypertension

The development of hypertension is multifactorial, involving several interconnected physiological mechanisms. These include:

• Increased Salt Absorption and Volume Expansion: Excessive sodium intake can lead to increased fluid retention, expanding blood volume and consequently raising blood pressure.
• Impaired Renin-Angiotensin-Aldosterone System (RAAS) Response: The RAAS plays a critical role in blood pressure regulation. Dysfunction in this system can lead to imbalances that promote hypertension.
• Increased Sympathetic Nervous System Activation: Overactivity of the sympathetic nervous system results in vasoconstriction and increased heart rate, both contributing to elevated blood pressure.

These pathophysiological changes ultimately lead to increased total peripheral resistance and afterload on the heart, culminating in sustained hypertension.

History and Physical Examination in Hypertension

Often, hypertension is asymptomatic, earning it the moniker “the silent killer.” It is frequently detected incidentally during routine blood pressure measurements. However, some patients present with symptoms indicative of end-organ damage resulting from prolonged hypertension, such as:

• Stroke-like symptoms or hypertensive encephalopathy
• Chest pain
• Shortness of breath
• Acute pulmonary edema

A physical examination may reveal elevated blood pressure as the only sign. However, a comprehensive examination should also look for indicators of secondary hypertension or underlying conditions, including:

• Coarctation of the aorta: Assess for radio-radial delay, radio-femoral delay, and blood pressure discrepancies between arms (or upper and lower limbs exceeding 20 mm Hg).
• Aortic valve disease: Listen for a systolic ejection murmur and a fourth heart sound (S4).
• Renovascular disease or fibromuscular dysplasia (FMD): Auscultate for renal and carotid bruits.
• Polycystic kidney disease: Palpate for bilaterally enlarged kidneys.
• Endocrine disorders: Examine for signs of hypercortisolism (thin skin, easy bruising, hyperglycemia) and thyroid disorders (palpable, painful, or enlarged thyroid).

The presence of an S4 heart sound suggests left ventricular hypertrophy and diastolic dysfunction, often a consequence of chronic hypertension. Lung rales and peripheral edema may indicate cardiac dysfunction and the chronicity of hypertension. These findings, while not directly diagnostic of hypertension itself, are critical in guiding the HTN differential diagnosis and assessing the impact of hypertension on other organ systems.

Evaluation and Diagnostic Approach to Hypertension

The American College of Cardiology (ACC) recommends diagnosing hypertension based on at least two office measurements taken on two separate occasions. The European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines suggest three office BP readings 1 to 2 minutes apart, with additional measurements only if the initial two readings differ by ≥ 10 mm Hg. The reported BP is then the average of the last two readings. Both guidelines advocate using higher BP readings to categorize patients into more severe stages/grades to ensure appropriate treatment intensity.

Accurate blood pressure measurement is crucial. Patients should be seated quietly for at least 5 minutes before measurement, using a cuff that covers 80% of the arm circumference. Incorrect cuff size can lead to inaccurate readings.

Ambulatory blood pressure monitoring (ABPM) is considered the gold standard for diagnosing hypertension. It is particularly valuable in identifying masked hypertension and white coat hypertension, which are essential considerations in the HTN differential diagnosis.

Further evaluation to assess for end-organ damage and guide management includes:

• 12-lead ECG: To detect left ventricular hypertrophy, and assess cardiac rate and rhythm.
• Fundoscopy: To examine for hypertensive retinopathy or maculopathy.
• Blood workup: Including complete blood count, ESR, creatinine, eGFR, electrolytes, HbA1c, thyroid profile, blood cholesterol levels, and serum uric acid.
• Urine albumin-to-creatinine ratio: To assess for kidney damage.
• Ankle-brachial pressure index (ABI): If peripheral arterial disease is suspected.
• Imaging: Carotid Doppler ultrasound, echocardiography, and brain imaging, as clinically indicated.

Treatment and Management Strategies for Hypertension

Management of hypertension encompasses both non-pharmacological and pharmacological approaches.

Non-Pharmacological Management: Lifestyle modifications are recommended for all individuals with elevated blood pressure, irrespective of age, gender, comorbidities, or cardiovascular risk. Patient education is paramount and should emphasize:

• Weight management
• Dietary salt restriction
• Smoking cessation
• Management of obstructive sleep apnea, if present
• Regular physical exercise

Patients must understand that these lifestyle changes are long-term commitments for effective hypertension management. Weight reduction alone can decrease systolic blood pressure by 5 to 20 mm Hg. While smoking may not directly elevate blood pressure, quitting significantly reduces long-term cardiovascular risks. Lifestyle changes can lead to up to a 15% reduction in overall cardiovascular events.

Pharmacological Therapy: Medications used to treat hypertension include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), thiazide diuretics, calcium channel blockers (CCBs), and beta-blockers (BBs). Drug selection is guided by patient age, race, comorbidities (such as renal dysfunction, left ventricular dysfunction, heart failure, and cerebrovascular disease), and guideline recommendations (JNC-8, ACC, ESC/ESH).

Key Guideline Recommendations:

• JNC-8: Recommends initiating pharmacological therapy at BP ≥ 140/90 mm Hg for individuals with diabetes mellitus (DM) and chronic kidney disease (CKD), and BP ≥ 150/90 mm Hg for individuals ≥ 60 years. For non-black individuals with DM, initial treatment should include a thiazide diuretic, CCB, or ACEI/ARB. For black individuals, including those with DM, treatment should include a thiazide diuretic and CCB. For all CKD patients, regardless of race or DM status, treatment should include an ACEI/ARB.
• ACC: Recommends assessing 10-year atherosclerotic cardiovascular disease (ASCVD) risk. Antihypertensive medications are generally started at BP ≥ 140/90 mm Hg. For high-risk populations (DM, CKD, established ASCVD, or 10-year ASCVD risk ≥ 10%), therapy may be initiated at lower BP thresholds, aiming for a target BP < 130/80 mm Hg.
• ESC/ESH: Recommends starting pharmacological therapy for grade 2 or 3 hypertension regardless of risk level, and for grade 1 hypertension with hypertension-mediated organ damage (HMOD). Grade 1 hypertension without HMOD requires high CVD risk or failure of lifestyle interventions before initiating drug therapy. For individuals ≥ 80 years, treatment starts at BP ≥ 160/90 mm Hg, aiming for < 160/90 mm Hg. For those aged 18-79 years, treatment starts at BP ≥ 140/90 mm Hg, aiming for < 140/90 mm Hg.

Renal Denervation: Renal denervation, an interventional procedure using catheter-based ablation of renal sympathetic nerves, is being investigated for resistant hypertension. However, trials like SPYRAL, RADIANCE, and SIMPLICITY-HTN have yielded mixed results, and it remains an investigational therapy.

Differential Diagnosis of Hypertension

A critical step in managing hypertension is considering HTN differential diagnosis, particularly to rule out secondary hypertension, especially in patients at age extremes (young or older) or those with sudden onset or resistant hypertension. Secondary hypertension is hypertension caused by an identifiable underlying condition. Conditions to consider in the HTN differential diagnosis include:

• Hyperaldosteronism: Excessive aldosterone production, often from adrenal adenomas or bilateral adrenal hyperplasia, leading to sodium retention and potassium excretion, resulting in hypertension.
• Coarctation of the aorta: A congenital narrowing of the aorta, typically distal to the subclavian artery, causing upper extremity hypertension and lower extremity hypotension.
• Renal artery stenosis: Narrowing of one or both renal arteries, often due to atherosclerosis or fibromuscular dysplasia, leading to reduced renal blood flow, RAAS activation, and hypertension.
• Chronic kidney disease (CKD): Impaired kidney function can disrupt fluid and electrolyte balance, and RAAS regulation, contributing to hypertension.
• Aortic valve disease: Conditions like aortic stenosis or regurgitation can increase afterload and contribute to hypertension.
• Obstructive Sleep Apnea (OSA): Intermittent hypoxia and sleep disruption in OSA can activate the sympathetic nervous system and contribute to hypertension.
• Thyroid Disorders: Both hyperthyroidism and hypothyroidism can affect blood pressure. Hyperthyroidism often leads to systolic hypertension, while hypothyroidism can cause diastolic hypertension.
• Pheochromocytoma: A rare tumor of the adrenal medulla that secretes catecholamines (epinephrine and norepinephrine), causing episodic or sustained hypertension, often with palpitations, sweating, and headaches.
• Cushing’s Syndrome: Excess cortisol production due to adrenal tumors, pituitary adenomas, or exogenous steroid use can cause hypertension, weight gain, and other characteristic features.
• Primary hyperparathyroidism: Excess parathyroid hormone can lead to hypercalcemia, which in some cases can contribute to hypertension.
• Medications and Substances: Numerous medications and substances can elevate blood pressure, including nonsteroidal anti-inflammatory drugs (NSAIDs), oral contraceptives, decongestants, stimulants, and illicit drugs like cocaine and amphetamines. A thorough medication history is crucial in HTN differential diagnosis.

Alt text: A close-up view of a blood pressure cuff being used on a patient’s arm during a routine blood pressure measurement, highlighting the standard medical procedure for hypertension screening.

Pertinent Studies and Ongoing Trials in Hypertension Research

Landmark randomized controlled trials (RCTs) have significantly shaped hypertension management guidelines. The SYST-EUR, HYVET, and SHEP studies were foundational for the JNC-8 recommendations. More recent trials like SPRINT, HOPE-3, the Gubbio population study, and the Framingham Heart Study, among others, informed the ACC and ESC/ESH guidelines. Ongoing research continues to refine treatment strategies and explore novel therapies for hypertension.

Treatment Planning and Management of Hypertension

Polytherapy, using two or more antihypertensive drugs, has become a standard approach in hypertension management, endorsed by both ACC and ESC/ESH guidelines. Two main strategies for initiating polytherapy are:

1. Simultaneous initiation: Starting with two or more drugs concurrently, typically an ACEI or ARB combined with a thiazide diuretic and/or a calcium channel blocker.
2. Stepwise titration: Initiating monotherapy and gradually increasing the dose to maximum before adding a second agent if blood pressure targets are not achieved.

Both approaches can effectively improve patient outcomes, provided patient compliance and treatment adherence are maintained. Guidelines recommend assessing blood pressure control 8 to 12 weeks after initiating or adjusting antihypertensive medication. Home blood pressure measurements (HBPM) or ABPM are recommended at baseline and approximately three months after starting therapy to monitor and document blood pressure control.

Toxicity and Adverse Effect Management of Antihypertensive Medications

Side effects from antihypertensive medications are generally mild and often resolve with dosage adjustments or temporary discontinuation. However, vigilant monitoring is crucial, especially during the initial phase of therapy when side effects are more frequent. Common side effects include:

• Hypotension (more common with CCBs and ACEIs/ARBs)
• Electrolyte imbalances (hyponatremia, hyperkalemia)
• Pedal edema (more common with CCBs)
• Renal dysfunction

ACEIs and ARBs are particularly associated with renal dysfunction and electrolyte imbalances, necessitating periodic monitoring of creatinine, potassium, and sodium levels.

Severe side effects, such as symptomatic hyperkalemia or hyponatremia, syncope, and acute kidney injury (AKI), require immediate drug discontinuation and may necessitate inpatient management. Consultations with nephrologists and cardiologists are often warranted in such cases. Once the acute issue resolves, medication may be cautiously reintroduced with close monitoring and frequent follow-up.

Angioedema is a rare but potentially life-threatening side effect of ACEIs and ARBs. It requires immediate discontinuation and is a lifelong contraindication to these drug classes.

Staging and Classification of Hypertension

Accurate staging of hypertension is essential for guiding treatment intensity and prognosis. The 2017 ACC guidelines classify hypertension as follows:[12]

• Normal: SBP < 120 mm Hg and DBP < 80 mm Hg
• Elevated: SBP 120-129 mm Hg and DBP < 80 mm Hg
• Stage 1 Hypertension: SBP 130-139 mm Hg or DBP 80-89 mm Hg
• Stage 2 Hypertension: SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg

White coat hypertension is defined as office BP ≥ 130/80 mm Hg but < 160/100 mm Hg, which normalizes (< 130/80 mm Hg) after at least 3 months of antihypertensive therapy. ABPM or HBPM is usually required for diagnosis.

Masked hypertension refers to normal office BP (SBP 120-129 mm Hg and DBP < 80 mm Hg) but elevated BP on ambulatory or home measurements (≥ 130/80 mm Hg).

The 2018 ESC/ESH guidelines classify hypertension as:[13]

• Optimal: SBP < 120 mm Hg and DBP < 80 mm Hg
• Normal: SBP 120-129 mm Hg and/or DBP 80-84 mm Hg
• High Normal: SBP 130-139 mm Hg and/or DBP 85-89 mm Hg
• Grade 1 Hypertension: SBP 140-159 mm Hg and/or DBP 90-99 mm Hg
• Grade 2 Hypertension: SBP 160-179 mm Hg and/or DBP 100-109 mm Hg
• Grade 3 Hypertension: SBP ≥ 180 mm Hg and/or DBP ≥ 110 mm Hg
• Isolated Systolic Hypertension: SBP ≥ 140 mm Hg and DBP < 90 mm Hg (further graded based on SBP ranges above)

ESC/ESH guidelines also provide cut-offs for HBPM and ABPM:

• Daytime (awake) mean: SBP ≥ 135 mm Hg and/or DBP ≥ 85 mm Hg
• Night-time (asleep) mean: SBP ≥ 120 mm Hg and/or DBP ≥ 70 mm Hg
• 24-hour mean: SBP ≥ 130 mm Hg and/or DBP ≥ 80 mm Hg
• Home BP mean: SBP ≥ 135 mm Hg and/or DBP ≥ 85 mm Hg

The JNC-8 report (2014) did not redefine hypertension but used previous JNC-7 definitions:[14]

• Normal: SBP < 120 mm Hg and DBP < 80 mm Hg
• Pre-Hypertension: SBP 120-139 mm Hg and DBP 80-89 mm Hg
• Stage 1 Hypertension: SBP 140-159 mm Hg and DBP 90-99 mm Hg
• Stage 2 Hypertension: SBP ≥ 160 mm Hg and DBP ≥ 100 mm Hg

Prognosis of Hypertension

Prognosis in hypertension is strongly linked to blood pressure control. Large meta-analyses demonstrate a near doubling of the risk of death from heart disease and stroke for every 20 mm Hg increase in SBP and 10 mm Hg increase in DBP.[15] Favorable outcomes depend on achieving and maintaining adequate blood pressure control. While hypertension is a progressive condition, effective management and lifestyle modifications can significantly delay or prevent complications like chronic kidney disease and renal failure.

Complications of Uncontrolled Hypertension

Uncontrolled hypertension significantly increases the risk of numerous complications, including:[15],[16]

1. Coronary heart disease (CHD)
2. Myocardial infarction (MI)
3. Stroke (CVA), ischemic or hemorrhagic
4. Hypertensive encephalopathy
5. Renal failure (acute or chronic)
6. Peripheral arterial disease
7. Atrial fibrillation
8. Aortic aneurysm
9. Death (primarily from CHD, vascular disease, or stroke)

Consultations and Interdisciplinary Approach to Hypertension Management

Resistant hypertension often requires a multidisciplinary approach. Collaboration between cardiologists, nephrologists, and hypertension specialists is essential for optimal management. Additionally, psychosocial counseling and dietary consultations with nutritionists and dietitians can significantly enhance patient adherence and outcomes.

Deterrence and Patient Education in Hypertension

Hypertension is a chronic condition requiring lifelong management. Comprehensive patient education on lifestyle modifications and pharmacological therapy is crucial for achieving and maintaining blood pressure control and preventing complications. Emphasis on weight management, regular physical activity, and limiting alcohol, tobacco, and smoking is paramount for reducing cardiovascular risk.

Enhancing Healthcare Team Outcomes in Hypertension Management

Nurses in emergency rooms and outpatient settings often play a vital role in the initial detection of hypertension. Prompt recognition and referral to a physician are essential, as many individuals with hypertension are unaware of their condition. Effective interprofessional communication is crucial, particularly for managing resistant hypertension, where a collaborative, interspecialty approach is most beneficial. An effective interprofessional team, including nursing staff, nurse practitioners, primary care physicians, cardiologists, nephrologists, and pharmacists, is essential for ensuring blood pressure control, monitoring patient compliance, managing potential toxicities and adverse effects, and ultimately minimizing future complications, reducing healthcare costs, and improving patient outcomes.

Review Questions

(Review questions from the original article are assumed to be included here if desired for completeness, but are not strictly required by the prompt.)

References

1. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II–Analysis of observational data within populations. BMJ. 1991 Apr 06;302(6780):815-8. [PMC free article: PMC1669164] [PubMed: 2025704]
2. Guyton AC, Coleman TG, Cowley AV, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972 May;52(5):584-94. [PubMed: 4337474]
3. Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, Vlietinck R. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995 Dec;26(6 Pt 1):919-24. [PubMed: 7490149]
4. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C, Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J, Karaman I, Lepe MP, O’Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said MA, Porteous D, Alver M, Poulter N, Farrall M, Gansevoort RT, Padmanabhan S, Mägi R, Stanton A, Connell J, Bakker SJ, Metspalu A, Shields DC, Thom S, Brown M, Sever P, Esko T, Hayward C, van der Harst P, Saleheen D, Chowdhury R, Chambers JC, Chasman DI, Chakravarti A, Newton-Cheh C, Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ, Howson JM, Tobin MD, Munroe PB, Ehret GB, Wain LV., International Consortium of Blood Pressure (ICBP) 1000G Analyses. BIOS Consortium. Lifelines Cohort Study. Understanding Society Scientific group. CHD Exome+ Consortium. ExomeBP Consortium. T2D-GENES Consortium. GoT2DGenes Consortium. Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium. International Genomics of Blood Pressure (iGEN-BP) Consortium. UK Biobank CardioMetabolic Consortium BP working group. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017 Mar;49(3):403-415. [PMC free article: PMC5972004] [PubMed: 28135244]
5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017 Jan 07;389(10064):37-55. [PMC free article: PMC5220163] [PubMed: 27863813]
6. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009 Apr 28;6(4):e1000058. [PMC free article: PMC2667673] [PubMed: 19399161]
7. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. [PubMed: 15652604]
8. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Tomaselli GF., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. [PubMed: 24222018]
9. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 05;387(10022):957-967. [PubMed: 26724178]
10. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. [PubMed: 26559744]
11. SPRINT Research Group. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. [PMC free article: PMC4689591] [PubMed: 26551272]
12. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. [PubMed: 29146535]
13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I., ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 01;39(33):3021-3104. [PubMed: 30165516]
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. [PubMed: 12748199]
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. [PubMed: 12493255]
16. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911. [PMC free article: PMC4042017] [PubMed: 24881994]